DRUG,LAB,VAR
AMIKACIN, AUC (mg/l*h),AUC
AMIKACIN, C1h/MIC ratio,CMIC
AMIKACIN, Cmax (mg/l),CMAX
AMIKACIN, Concentration (mg/l),DV
AMIKACIN,Clearance (L/h),CL
AMIKACIN,Volume of distribution (L),V
AMIKACIN,Central Volume of distribution (L),V1
AMIKACIN,Central Volume of distribution (L),V2
AMIKACIN,Peripheral Volume of distribution (L),V3
AMIKACIN,Intercompartmental clearance (L/h),Q
AMIKACIN,Intercompartmental clearance (L/h),Q2
AMIKACIN,Intercompartmental clearance (L/h),Q3
AMIKACIN,Intercompartmental clearance (L/h),Q12
AMIKACIN,Intercompartmental clearance (L/h),Q21
AMIKACIN,Intercompartmental clearance (L/h),Q13
AMIKACIN,Intercompartmental clearance (L/h),Q31
AMIKACIN,Weight (kg),WT
AMIKACIN,Age (yrs),AGE
AMIKACIN,Creatinine Clearance (ml/min),CRCL
AMIKACIN,Body Mass Index (kg/m2),BMI
AMIKACIN,Lean Body Mass (kg),LBM
AMIKACIN,Height (cm),HT
AMIKACIN,Serum creatinine (g/dL),SCR
AMIKACIN,Body Surface Area (m2),BSA
DOCETAXEL, AUC (mg/l*h),AUC
DOCETAXEL, Cmax (mg/l),CMAX
DOCETAXEL, Concentration (mg/l),DV
DOCETAXEL,Clearance (L/h),CL
DOCETAXEL,Volume of distribution (L),V
DOCETAXEL,Central Volume of distribution (L),V1
DOCETAXEL,Central Volume of distribution (L),V2
DOCETAXEL,Peripheral Volume of distribution (L),V3
DOCETAXEL,Intercompartmental clearance (L/h),Q
DOCETAXEL,Intercompartmental clearance (L/h),Q2
DOCETAXEL,Intercompartmental clearance (L/h),Q3
DOCETAXEL,Intercompartmental clearance (L/h),Q12
DOCETAXEL,Intercompartmental clearance (L/h),Q21
DOCETAXEL,Intercompartmental clearance (L/h),Q13
DOCETAXEL,Intercompartmental clearance (L/h),Q31
DOCETAXEL,Weight (kg),WT
DOCETAXEL,Age (yrs),AGE
DOCETAXEL,Creatinine Clearance (ml/min),CRCL
DOCETAXEL,Body Mass Index (kg/m2),BMI
DOCETAXEL,Lean Body Mass (kg),LBM
DOCETAXEL,Height (cm),HT
DOCETAXEL,Serum creatinine (g/dL),SCR
DOCETAXEL,Body Surface Area (m2),BSA
GABAPENTIN, AUC (mg/l*h),AUC
GABAPENTIN, Cmax (mg/l),CMAX
GABAPENTIN, Concentration (mg/l),DV
GABAPENTIN,Clearance (L/h),CL
GABAPENTIN,Volume of distribution (L),V
GABAPENTIN,Central Volume of distribution (L),V1
GABAPENTIN,Peripheral Volume of distribution (L),V2
GABAPENTIN,Peripheral Volume of distribution (L),V3
GABAPENTIN,Intercompartmental clearance (L/h),Q
GABAPENTIN,Intercompartmental clearance (L/h),Q2
GABAPENTIN,Intercompartmental clearance (L/h),Q3
GABAPENTIN,Intercompartmental clearance (L/h),Q12
GABAPENTIN,Intercompartmental clearance (L/h),Q21
GABAPENTIN,Intercompartmental clearance (L/h),Q13
GABAPENTIN,Intercompartmental clearance (L/h),Q31
GABAPENTIN,Weight (kg),WT
GABAPENTIN,Age (yrs),AGE
GABAPENTIN,Creatinine Clearance (ml/min),CRCL
GABAPENTIN,Body Mass Index (kg/m2),BMI
GABAPENTIN,Lean Body Mass (kg),LBM
GABAPENTIN,Height (cm),HT
GABAPENTIN,Serum creatinine (g/dL),SCR
GABAPENTIN,Body Surface Area (m2),BSA
MEROPENEM, AUC (mg/l*h),AUC
MEROPENEM, Cmax (mg/l),CMAX
MEROPENEM, T>MIC (%),TMIC
MEROPENEM, Concentration (mg/l),DV
MEROPENEM,Clearance (L/h),CL
MEROPENEM,Volume of distribution (L),V
MEROPENEM,Central Volume of distribution (L),V1
MEROPENEM,Central Volume of distribution (L),V2
MEROPENEM,Peripheral Volume of distribution (L),V3
MEROPENEM,Intercompartmental clearance (L/h),Q
MEROPENEM,Intercompartmental clearance (L/h),Q2
MEROPENEM,Intercompartmental clearance (L/h),Q3
MEROPENEM,Intercompartmental clearance (L/h),Q12
MEROPENEM,Intercompartmental clearance (L/h),Q21
MEROPENEM,Intercompartmental clearance (L/h),Q13
MEROPENEM,Intercompartmental clearance (L/h),Q31
MEROPENEM,Weight (kg),WT
MEROPENEM,Age (yrs),AGE
MEROPENEM,Creatinine Clearance (ml/min),CRCL
MEROPENEM,Body Mass Index (kg/m2),BMI
MEROPENEM,Lean Body Mass (kg),LBM
MEROPENEM,Height (cm),HT
MEROPENEM,Serum creatinine (g/dL),SCR
MEROPENEM,Body Surface Area (m2),BSA
MYCACID, AUC (mg/l*h),AUC
MYCACID, Cmax (mg/l),CMAX
MYCACID, Concentration (mg/l),DV
MYCACID,Clearance (L/h),CL
MYCACID,Volume of distribution (L),V
MYCACID,Central Volume of distribution (L),V1
MYCACID,Central Volume of distribution (L),V2
MYCACID,Peripheral Volume of distribution (L),V3
MYCACID,Intercompartmental clearance (L/h),Q
MYCACID,Intercompartmental clearance (L/h),Q2
MYCACID,Intercompartmental clearance (L/h),Q3
MYCACID,Intercompartmental clearance (L/h),Q12
MYCACID,Intercompartmental clearance (L/h),Q21
MYCACID,Intercompartmental clearance (L/h),Q13
MYCACID,Intercompartmental clearance (L/h),Q31
MYCACID,Weight (kg),WT
MYCACID,Age (yrs),AGE
MYCACID,Creatinine Clearance (ml/min),CRCL
MYCACID,Body Mass Index (kg/m2),BMI
MYCACID,Lean Body Mass (kg),LBM
MYCACID,Height (cm),HT
MYCACID,Serum creatinine (g/dL),SCR
MYCACID,Body Surface Area (m2),BSA
RIVAROXABAN, AUC (mg/ml*h),AUC
RIVAROXABAN, Cmax (mg/ml),CMAX
RIVAROXABAN, Concentration (mg/ml),DV
RIVAROXABAN,Clearance (L/h),CL
RIVAROXABAN,Volume of distribution (L),V
RIVAROXABAN,Central Volume of distribution (L),V1
RIVAROXABAN,Central Volume of distribution (L),V2
RIVAROXABAN,Peripheral Volume of distribution (L),V3
RIVAROXABAN,Intercompartmental clearance (L/h),Q
RIVAROXABAN,Intercompartmental clearance (L/h),Q2
RIVAROXABAN,Intercompartmental clearance (L/h),Q3
RIVAROXABAN,Intercompartmental clearance (L/h),Q12
RIVAROXABAN,Intercompartmental clearance (L/h),Q21
RIVAROXABAN,Intercompartmental clearance (L/h),Q13
RIVAROXABAN,Intercompartmental clearance (L/h),Q31
RIVAROXABAN,Weight (kg),WT
RIVAROXABAN,Age (yrs),AGE
RIVAROXABAN,Creatinine Clearance (ml/min),CRCL
RIVAROXABAN,Body Mass Index (kg/m2),BMI
RIVAROXABAN,Lean Body Mass (kg),LBM
RIVAROXABAN,Height (cm),HT
RIVAROXABAN,Serum creatinine (g/dL),SCR
RIVAROXABAN,Body Surface Area (m2),BSA
EVACETRAPIB, AUC (ng/ml*h),AUC
EVACETRAPIB, Cmax (ng/ml),CMAX
EVACETRAPIB, Concentration (ng/ml),DV
EVACETRAPIB,Clearance (L/h),CL
EVACETRAPIB,Volume of distribution (L),V
EVACETRAPIB,Central Volume of distribution (L),V1
EVACETRAPIB,Central Volume of distribution (L),V2
EVACETRAPIB,Peripheral Volume of distribution (L),V3
EVACETRAPIB,Intercompartmental clearance (L/h),Q
EVACETRAPIB,Intercompartmental clearance (L/h),Q2
EVACETRAPIB,Intercompartmental clearance (L/h),Q3
EVACETRAPIB,Intercompartmental clearance (L/h),Q12
EVACETRAPIB,Intercompartmental clearance (L/h),Q21
EVACETRAPIB,Intercompartmental clearance (L/h),Q13
EVACETRAPIB,Intercompartmental clearance (L/h),Q31
EVACETRAPIB,Weight (kg),WT
EVACETRAPIB,Age (yrs),AGE
EVACETRAPIB,Creatinine Clearance (ml/min),CRCL
EVACETRAPIB,Body Mass Index (kg/m2),BMI
EVACETRAPIB,Lean Body Mass (kg),LBM
EVACETRAPIB,Height (cm),HT
EVACETRAPIB,Serum creatinine (g/dL),SCR
EVACETRAPIB,Body Surface Area (m2),BSA
